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Abstract
This paper presents a DEA (Data Envelopment Analysis)/ Malmquist index methodol-
ogy for measuring the R&D efficiency change of the Japanese pharmaceutical industry.
Letting each of ten firms each year be a separate DMU (Decision-Making Unit) and
employing one input and three outputs in the DEA, and using the cumulative frontier
shift component on average proposed in the Malmquist index analysis, we quite ob-
viously show the industry-wide R&D efficiency change for the period 1982-2001. The
results empirically reveal that the R&D efficiency of the Japanese industry, which has
seemed elusive, has surely gotten worse almost monotonically for these twenty years
at least as to the pharmaceutical one.
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1 INTRODUCTION
This paper measures R&D efficiency of Japanese pharmaceutical firms and examines how
R&D efficiency at the industry level has changed over time. R&D in firms, that can be
considered as a stage prior to production, would be as important as production. But we
have not quantitatively analyzed R&D efficiency so much as productivity. The lack of
how to measure R&D efficiency would be the main reason. In considering the input and
output of R&D, we cannot immediately specify what to be as the output, compared with
R&D investment as the input. Geisler (1995) and Brown and Svenson (1998) list pub-
lished articles, patents, new products, etc. as the output. This multiplicity of the output
prevents from analyzing R&D efficiency by means of the ordinary production function,
i.e., parametric, approach. After all, true efficiency in R&D has yet been elusive.
∗Corresponding author. E-mail: hashimot@sk.tsukuba.ac.jp
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Thus it is not easy to measure R&D efficiency, so that we have seldom observed its
chronological transition at the industry level. Has it gradually gotten better as incorpo-
rating some innovations into process like productivity could be expected? For the recent
Japanese industry, it might not or might have even worsened (Sakakibara and Tsujimoto,
2003). For also the pharmaceutical industry in the world, it is said that the R&D efficiency
is recently in decline (Tollman et al., 2004). Taking up the Japanese pharmaceutical in-
dustry, we verify whether the R&D efficiency has gotten better or worse for the latest
twenty years.
In order to analyze the R&D efficiency, we employ DEA (Data Envelopment Analysis)
(e.g., Charnes et al., 1994, Cooper et al., 2000). DEA is a non-parametric method that
can measure the relative efficiency, i.e., DEA efficiency, of objects called DMUs (Decision-
Making Units) with multiple inputs and multiple outputs. Although DEA could be applied
to various fields other than the standard efficiency analysis (e.g., Hashimoto and Ishikawa,
1993, Hashimoto, 1996), the DEA characteristic that can deal with even multiple outputs
has enabled to measure the efficiency of a variety of DMU sets in also the original efficiency
analysis. For example, Nasierowski and Arcelus (2003) recently measure the efficiency of
45 national innovation systems with two inputs and three outputs using DEA. However,
we can find no DEA analyses of firms’ R&D efficiency except for Honjo and Haneda (1998).
They try to analyze the R&D efficiency of fourteen Japanese pharmaceutical firms with
one input and two outputs for the period 1977-1991. Refining their analyses, we also
preparatorily do DEA analyses using the panel data of ten pharmaceutical firms for 1982-
2001. But we should note that the ordinary DEA cannot analyze as taking the DEA
efficiency frontier shifting over time into consideration.
Then, we introduce DEA/ Malmquist index analysis (e.g., Fa¨re et al., 1998, Thanas-
soulis, 2001) to examine time series change in R&D efficiency at the industry level. The
Malmquist index can measure the ratio of DEA efficiencies in two different time periods
with shifting DEA efficiency frontiers. Although we recently have some DEA/ Malmquist
index applications, most of which are applied to productivity like Gonza´lez and Gasco´n
(2004). The Malmquist index can be decomposed into two components: “catch-up” and
“frontier shift”. The former measures how much closer to the frontier a DMU, i.e., a firm,
moves, while the latter does the movement of the frontier. Since the frontier is composed
of the DEA efficient DMUs among all the firms in a time period, the frontier shift means
the change at the industry level, not at the firm one. Using this frontier shift, we de-
vise to quite obviously display the R&D efficiency change of the Japanese pharmaceutical
industry for the period 1982-2001.
2 DATA TO MEASURE R&D EFFICIENCY
To DEA-analyze the R&D efficiency and its change of the Japanese pharmaceutical indus-
try, we provide four data panels as follows: Each panel is ten firms × twenty years. That
is, the sample period is the latest 1982-2001 and the ten pharmaceutical firms are Takeda,
Sankyo, Yamanouchi, Daiichi, Eisai, Shionogi, Fujisawa, Chugai, Tanabe and Yoshitomi.
They are all big enterprises driving R&D and seem homogeneous as professional-medicine
makers. Although we first took the biggest thirteen pharmaceutical firms of Japan into
consideration, Kyowa-Hakko and Meiji-Seika were excluded because each of their medicine
sales did not reach to fifty percent of its whole sales. We also excluded Taisho because of
its characteristic as a popular-medicine maker peculiar vs the other firms.
DEA relatively evaluates how efficiently DMUs convert multiple inputs into multiple
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outputs. That is, any DMU producing more outputs with fewer inputs is judged relatively
efficient. In DEA-analyzing the R&D efficiency of pharmaceutical firms as the DMUs,
we can straightforward list R&D expenditure (billion yen a year) as the input. As the
multiple outputs, we consider the following three: We first list patents (the number of
patent applications publicly published a year) as a proxy of invention. R&D activities in
firms can be divided into two: one aiming at “product innovation” and the other aiming
at “process innovation”. While the former contributes sales increase through product
discrimination, the latter does profit increase through cost reduction (Odagiri, 1987).
Corresponding to these respectively, we list pharmaceutical sales (ten billion yen a year)
and operating profit (billion yen a year) as the additional outputs.
We collect annual data to the one input and three outputs, for the ten firms in the
period 1982-2001, from Data Book (Tokyo: Japan Pharmaceutical Manufacturers Associ-
ation) and NEEDS Database (Tokyo: Nihon Keizai Shimbun, Inc.). The four indicators
except for patents are all deflated to the 2001 value.
3 PRELIMINARY DEA ANALYSES OF R&D EFFICIENCY
We here apply the data collected to a DEA model measuring the relative DEA efficiency
of target DMU j0, hj0(0 ≤ hj0 ≤ 1). We employ the CCR (Charnes, Cooper and Rhodes,
1978) model, and its input-oriented and envelopment form is formulated as the following
LP (Linear Programming):
Minimize hj0 = θ − ²
(
t∑
r=1
s+r +
m∑
i=1
s−i
)
= θ − ²σ
subject to
n∑
j=1
λjyrj − s+r = yrj0 , r = 1, ..., t, (1)
n∑
j=1
λjxij − θxij0 + s−i = 0, i = 1, ...,m,
λj , s
+
r , s
−
i ≥ 0, j = 1, ..., n, r = 1, ..., t, i = 1, ...,m,
(θ unconstrained),
where θ, λj , s+r , s
−
i = decision variables to LP, yrj = the amount of output r from DMU
j, xij = the amount of input i to DMU j, n = the number of DMUs, t = the number of
outputs, m = the number of inputs, ² = a positive non-Archimedean infinitesimal. We
can find DEA efficiencies of all the DMUs by solving LP (1) n times, setting each DMU
as target DMU j0 in turn. Here, DMU j0 with the minimum h∗j0 = 1 is judged DEA
efficient, but DMU j0 with h∗j0 = 1 − ²σ∗(σ∗ 6= 0) ∼= 1 can be discriminated as “weakly
DEA efficient”.
Three preliminary DEA analyses of the ten pharmaceutical firms are shown in Ap-
pendix. We should note the following: First, we employ the CCR model assuming the
constant returns-to-scale, not the variable returns-to-scale, because the ten sample firms
are all big enterprises and can be regarded comparable under the assumption (see Ap-
pendix). Second, as data measuring the R&D efficiency, we apply input and output data
of the same year, not using the input data of a year together with the output data of some
years later. Surely, the effect of input would emerge on the output some time later. How-
ever, we have no knowledge of how the delay is. Therefore, we might had better consider
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that the R&D efficiency measured here means the efficiency of rather the R&D sector in
firms, that must be settled an account by the annual data, than the R&D activity itself.
From the results of DEA analyses, the R&D efficiency of Japanese pharmaceutical firms
do not seem to have gotten better for the period 1982-2001 at all. But these analyses are all
at the firm level, and cannot exactly grasp how the R&D efficiency of the pharmaceutical
industry has changed in this period. This is a limit of the ordinary DEA single-handed
analyses.
4 CHANGE IN R&D EFFICIENCY FOR 1982-2001
To quantitatively show the R&D efficiency change of the industry for 1982-2001, we here
introduce the DEA/ Malmquist index analysis and apply the same data collected.
4.1 DEA/ Malmquist Index Analysis
DEA/Malmquist index analysis measures the Malmquist (productivity) index (Malmquist,
1953, Caves et al., 1982) in the DEA frame:
In Figure 1, a single input and output DEA case, DMU j0 being evaluated was at
point A in period α and line OCD shows the then CCR DEA efficiency frontier. Suppose
that in period β (β > α), DMU j0 has moved to point B and the frontier itself has also
shifted to line OEF. DEA efficiency change of DMU j0 can be measured by the ratio of
DEA efficiency in period β to that in period α, but the frontier has shifted, so that we
compute the geometric mean of ratios as to the two frontiers in periods α and β. This is
the DEA (CCR input oriented)/ Malmquist index of DMU j0 between periods α and β
MIj0 [α, β] ≡
(
QD/QB
PC/PA
· QF/QB
PE/PA
)1/2
. (2)
Here, MI > 1 means gain in DEA efficiency of DMU j0 from period α to β, whileMI = 1
and MI < 1 mean the status quo and loss respectively.
Transforming formula (2), Malmquist index can be decomposed into two components
as follows:
MIj0 [α, β] =
QF/QB
PC/PA
×
(
PC
PE
· QD
QF
)1/2
(3)
= CUj0 [α, β]× FSj0 [α, β]
=
QF/QB
PC/PA
×
(
PC/PA
PE/PA
· QD/QB
QF/QB
)1/2
. (4)
As each term of formula (3) shows, CU indicates Catch-Up index, i.e, CU > 1 means that
DMU j0 has moved closer to the period β frontier than to the period α one. CU = 1 and
CU < 1 mean that it has the same distance and that it has moved farther, respectively.
FS indicates Frontier Shift index, and FS > 1 means gain in DEA efficiency frontier shift
from period α to β measured from the location of DMU j0, i.e., the frontier has moved
so as to have the more output with the fewer input as shown in Figure 1. FS = 1 and
FS < 1 mean no change and loss respectively.
Since PE/PA in Figure 1 is, for example, the (radial) DEA efficiency of the period
α DMU j0 measured by means of the period β frontier, we denote it as θ[Dα, F β]. Then
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from formula (4),
MIj0 [α, β] =
θ[Dβ, F β]
θ[Dα, Fα]
×
(
θ[Dα, Fα]
θ[Dα, F β]
· θ[D
β, Fα]
θ[Dβ, F β]
)1/2
. (5)
In LP (1), ignoring the infinitesimal term, regarding s+r and s
−
i as slack variables, denoting
yj = [y1j , ..., ytj ], xj = [x1j , ..., xmj ] and letting xαj = xj in period α, θ[D
α, Fα] can be
obtained as the minimum of the following LP, the ordinary DEA model:
Minimize θ
subject to
n∑
j=1
λjy
α
j ≥ yαj0 , (6)
n∑
j=1
λjx
α
j − θxαj0 ≤ 0,
λj ≥ 0, j, ..., n,
(θ unconstrained).
θ[Dβ, F β] can also be obtained by the LP (6) replaced α by β.
While θ[Dα, F β] is obtained as the minimum of
Minimize θ
subject to
n∑
j=1
λjy
β
j ≥ yαj0 , (7)
n∑
j=1
λjx
β
j − θxαj0 ≤ 0,
λj ≥ 0, j, ..., n,
(θ unconstrained),
this forms the DEA exclusion model (Andersen and Petersen, 1993). Finally, we can
obtain θ[Dβ, Fα] by also the DEA exclusion model (7) exchanged α and β.
4.2 Cumulative Malmquist Index
Applying the data to models (6) and (7), and through formula (5), we can compute the
catch-up CUj0 [α, β], the frontier shift FSj0 [α, β] and the Malmquist MIj0 [α, β] indices.
These indices for a year are usually compared to the preceding year. However, such suc-
cessive indices do not seem appropriate to grasp the chronological change for twenty years
in the wide range of vision. Therefore, we propose to employ another index than the suc-
cessive one. Tables 1-3 respectively show MIj0 [1982, β], CUj0 [1982, β] and FSj0 [1982, β],
β = 1982, ..., 2001. They are all compared to the start year 1982. Since they involve their
successive changes up to year β, we call them cumulative indices. The cumulative index
values when β = 1982 could be considered 1. Since the Malmquist index is multiplicative,
we here employ geometric means, not arithmetic ones, as all the averages.
The Malmquist index indicates the R&D efficiency change of a firm taking the R&D
efficiency frontier shifting into consideration. Thus Table 1 shows that the R&D efficiency
of Japanese pharmaceutical firms has gotten worse in average at the annual rate 4.7%
for 1982-2001, and has in year 2001 dropped to under 40% of the start year 1982. This
implies a big loss in firms’ R&D efficiency. We should note that all the ten firms have
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this decreasing R&D efficiency. The worst for this period would be Chugai and Fujisawa
while the last worst, Takeda. Since the annual catch-up rate on average in Table 2 is 0.993
(nearly 1), we find that the Malmquist (Table 1) would depend much more on the frontier
shift (Table 3) than the catch-up (Table 2).
The catch-up measures how much closer to the yearly R&D efficiency frontier a firm
moves. For only the catch-up, Takeda, Daiichi and Tanabe have gotten even better for
this period (Table 2). The cumulative catch-up is the ratio of R&D efficiency of a firm in
year β to that in year 1982. Therefore, in Table A1, the cross-section DEA efficiency of a
year divided by that of year 1982 is the catch-up value of the year in Table 2. That is, for
Sankyo, the values in Tables 2 and A1 are equal, and for Daiichi, for example, the values
in Table 2 do not exceed 1/0.67 = 1.501, i.e., its upper limit.
Picking up columns from Tables 1-3, we can draw a graph of the three cumulative
indices for each firm. Figure 2 for Sankyo and Figure 3 for Daiichi are examples: In
Figure 2, the catch-up shows that Sankyo has been on the R&D efficiency frontier from
the start year 1982 to 1998. The Malmquist, that has been equal to the frontier shift for
these years, has in year 2001 gone worsened to 25.4% of the start year. For Daiichi (Figure
3), as is mentioned before, the catch-up has gotten better since the start year and it has
reached to the upper limit in years 1985-1987 and 1989. The cumulative Malmquist indices
are also over 1 for 1985-1989, so that this shows that the R&D efficiency of Daiichi has
improved for this period compared to the start year. In this way, we can quantitatively
show the chronological changes in a firm’s R&D efficiency using the three cumulative
indices.
4.3 R&D Efficiency Loss by the Industry
The cumulative frontier shift index indicates the move of the industry’s R&D efficiency
frontier from the viewpoint (location) of each firm. Therefore, the frontier shift on average
(Table 3) could be an appropriate indicator to measure the R&D efficiency change at
the industry level. The annual change rate 0.960 means that the R&D efficiency of the
Japanese pharmaceutical industry has worsened at the annual rate 4.0% for 1982-2001.
That is, the great R&D efficiency frontier shift reverse to as shown in Figure 1 has occurred.
Figure 4 is a graph of the cumulative frontier shift on average in Table 3. It shows that
the R&D efficiency of the industry has gotten worse to about 70% of the start year 1982
just in year 1984, and has finally dropped to 45.8% in year 2001 via the lowest 38.9% in
2000. Although there are observed the recoveries in years 1993 and 2001, we must say that
the industry’s R&D efficiency has almost monotonically been decreasing throughout the
period. Thus, we could quite obviously show how the industry-wide R&D efficiency has
changed, which implies the great loss in R&D efficiency by the Japanese pharmaceutical
industry for the period 1982-2001.
5 SUMMARY AND CONCLUSIONS
This study presented a DEA/ Malmquist index methodology for measuring the R&D
efficiency change at the industry level. Using the cumulative frontier shift index proposed
in the methodology, we could quantitatively show the time series change in the R&D
efficiency of the Japanese pharmaceutical industry for the period 1982-2001. We here
found the great R&D efficiency loss by the industry throughout the period and that the
industry’s R&D efficiency had dropped in year 2001 to even under fifty percent of the
start year 1982.
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Since year 1982, why has annually each firm continued to enormously invest in the
R&D in spite of the decreasing efficiency? Haneda and Odagiri (1998) indicate that R&D
investment affects the value of firm. Because of such factors other than efficiency, the firm
might have to continue to invest in R&D. Whether this is true, and whether the recent
loss in R&D efficiency comes under the other industries are up to the further studies. In
also these study fields, the methodology presented in this paper would be valid to examine
them.
Appendix
Solving DEA model (1) with one input and three outputs (m = 1, t = 3), we obtain DEA
efficiencies h∗j0 shown in Tables A1-A3. In all these Tables, value 1 indicates DEA efficient,
including no weakly DEA efficient DMUs. We should here notice rather the location of
value 1 than the DEA efficiency values themselves. Table A1 shows the results of twenty
DEA cross-section analyses with ten DMUs (n = 10), i.e., the cross-section DEA by
year, treating each firm as a separate DMU. It is noteworthy that Takeda and Yoshitomi,
respectively the largest and the smallest scaled firms measured by the R&D expenditure,
both are judged DEA efficient in multiple time periods. This affirms the employment of
CCR model assuming the constant returns-to-scale. We find that Sankyo would have been
most efficient in R&D because it is judged DEA efficient in seventeen years among the
twenty. On the contrary, Eisai has never been DEA efficient for these twenty years.
Table A2 shows the results of ten DEA time series analyses with twenty DMUs (n =
20), i.e., the time series DEA (Cooper et al., 1995, Hashimoto and Kodama, 1997) by firm,
treating each year as a separate DMU. We find that all the firms have their own DEA
efficient years in the first two years, 1982-1983. And only three firms, Takeda, Sankyo and
Yoshitomi, have them in also the last half of the period, 1992-2001. There are no firms
having them in the third quarter of the period, 1992-1996. Table A3 shows the results
of a DEA panel analysis with 200 DMUs (n = 200 = 10 firms× 20 years), i.e., the panel
DEA treating each firm each year as a separate DMU. We find that the frontier in this
DEA is composed of only two DMUs, Sankyo 1982 and Yamanouchi 1988. These are most
efficient DMUs among the 200 and both are in the first half of the period.
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Figure 1. DEA Efficiency Change with the Frontier Shifting over Time.
Figure 2.  Cumulative Indices for Sankyo.
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Figure 3.  Cumulative Indices for Daiichi.
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Figure 4.  R&D Efficiency Loss by the Industry for 1982-2001.
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Table 1.  Cumulative Malmquist Index MI j0 [1982, β], β = 1982, …, 2001
Year Firm Aver-
  β Takeda Sankyo Yama- Daiichi Eisai Shio- Fuji- Chugai Tanabe Yoshi- age
nouchi nogi sawa tomi
1982 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
1983 0.897 0.781 0.852 0.915 0.862 0.870 0.827 1.043 0.877 0.656 0.853
1984 0.819 0.663 0.800 0.882 0.700 0.860 0.825 0.816 0.838 0.696 0.786
1985 0.837 0.705 0.806 1.080 0.630 0.706 0.610 0.780 0.760 0.612 0.742
1986 0.811 0.613 0.748 1.184 0.718 0.747 0.731 0.704 0.953 0.501 0.752
1987 0.906 0.528 0.863 1.095 0.652 0.738 0.640 0.574 0.986 0.576 0.734
1988 0.876 0.557 0.934 1.063 0.689 0.727 0.741 0.511 0.991 0.633 0.752
1989 0.747 0.590 0.888 1.118 0.718 0.668 0.650 0.494 0.711 0.910 0.731
1990 0.689 0.647 0.841 0.945 0.643 0.611 0.608 0.462 0.704 0.961 0.695
1991 0.621 0.650 0.780 0.817 0.613 0.546 0.578 0.498 0.683 0.805 0.651
1992 0.614 0.573 0.638 0.724 0.567 0.524 0.558 0.458 0.670 0.531 0.581
1993 0.707 0.745 0.734 0.814 0.683 0.587 0.567 0.574 0.705 0.886 0.693
1994 0.639 0.583 0.683 0.796 0.688 0.615 0.573 0.540 0.688 0.699 0.647
1995 0.770 0.567 0.685 0.815 0.681 0.613 0.554 0.501 0.638 0.720 0.648
1996 0.765 0.529 0.597 0.714 0.667 0.592 0.507 0.435 0.615 0.591 0.594
1997 0.730 0.535 0.575 0.623 0.535 0.540 0.448 0.314 0.621 0.612 0.541
1998 0.811 0.511 0.395 0.576 0.411 0.521 0.391 0.334 0.549 0.540 0.489
1999 0.980 0.500 0.512 0.726 0.503 0.598 0.375 0.334 0.636 0.534 0.545
2000 0.751 0.254 0.342 0.466 0.410 0.390 0.223 0.229 0.558 0.372 0.372
2001 0.915 0.254 0.358 0.506 0.462 0.460 0.234 0.230 0.654 0.316 0.398
Annual change rate
0.995 0.930 0.947 0.965 0.960 0.960 0.926 0.926 0.978 0.941 0.953
Table 2.  Cumulative Catch-Up Index CU j0 [1982, β], β = 1982, …, 2001
Year Firm Aver-
  β Takeda Sankyo Yama- Daiichi Eisai Shio- Fuji- Chugai Tanabe Yoshi- age
nouchi nogi sawa tomi
1982 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
1983 1.046 1.000 1.003 1.172 1.005 1.013 0.944 1.237 1.077 0.847 1.029
1984 1.036 1.000 1.123 1.364 0.928 1.110 1.188 1.122 1.075 1.252 1.114
1985 1.128 1.000 1.123 1.501 0.840 0.917 0.859 1.031 1.003 0.969 1.023
1986 1.010 1.000 1.053 1.501 0.909 0.944 1.188 1.028 1.161 0.968 1.065
1987 1.058 1.000 1.123 1.501 0.855 0.890 0.931 0.856 1.161 1.462 1.063
1988 1.006 1.000 1.123 1.366 0.817 0.868 1.025 0.846 1.161 1.488 1.051
1989 1.046 1.000 1.123 1.501 0.969 0.948 1.120 0.742 1.027 1.488 1.075
1990 0.920 1.000 1.123 1.352 0.861 0.826 1.004 0.682 0.978 1.488 0.999
1991 0.906 1.000 1.094 1.202 0.831 0.740 0.996 0.774 0.910 1.488 0.974
1992 0.962 1.000 1.033 1.316 0.904 0.824 1.188 0.856 1.119 1.488 1.051
1993 1.031 1.000 0.971 1.247 0.920 0.892 1.001 0.892 1.087 1.488 1.040
1994 1.035 1.000 1.100 1.404 1.053 1.065 1.142 1.039 1.161 1.488 1.139
1995 1.250 1.000 1.123 1.384 1.126 1.081 1.188 1.005 1.092 1.469 1.163
1996 1.250 1.000 1.123 1.412 1.195 1.076 1.188 1.129 1.105 1.331 1.175
1997 1.250 1.000 1.120 1.341 0.923 0.980 1.053 0.739 1.153 1.488 1.085
1998 1.250 1.000 0.770 1.321 0.781 0.963 0.963 0.919 1.050 1.488 1.028
1999 1.250 0.933 1.123 1.465 1.008 1.147 1.027 0.750 1.161 1.379 1.106
2000 1.250 0.813 0.836 1.249 0.878 0.905 0.744 0.634 1.161 1.413 0.958
2001 1.250 0.654 0.751 1.183 0.816 0.949 0.598 0.628 1.161 0.996 0.869
Annual change rate
1.012 0.978 0.985 1.009 0.989 0.997 0.973 0.976 1.008 1.000 0.993
 The upper limit for each firm.
Table 3.  Cumulative Frontier Shift Index FS j0 [1982, β], β = 1982, …, 2001
Year Firm Aver-
  β Takeda Sankyo Yama- Daiichi Eisai Shio- Fuji- Chugai Tanabe Yoshi- age
nouchi nogi sawa tomi
1982 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
1983 0.858 0.781 0.849 0.781 0.858 0.858 0.876 0.843 0.814 0.775 0.828
1984 0.790 0.663 0.712 0.647 0.754 0.775 0.694 0.727 0.779 0.556 0.706
1985 0.742 0.705 0.717 0.720 0.750 0.770 0.710 0.757 0.758 0.631 0.725
1986 0.803 0.613 0.711 0.789 0.790 0.791 0.615 0.685 0.821 0.518 0.706
1987 0.857 0.528 0.768 0.730 0.763 0.829 0.687 0.671 0.849 0.394 0.691
1988 0.871 0.557 0.832 0.778 0.843 0.838 0.723 0.604 0.853 0.425 0.715
1989 0.715 0.590 0.791 0.745 0.741 0.705 0.580 0.666 0.692 0.612 0.680
1990 0.748 0.647 0.748 0.699 0.746 0.739 0.606 0.677 0.720 0.646 0.696
1991 0.685 0.650 0.713 0.679 0.738 0.738 0.581 0.644 0.751 0.541 0.669
1992 0.638 0.573 0.617 0.550 0.627 0.636 0.470 0.535 0.599 0.357 0.553
1993 0.686 0.745 0.756 0.653 0.743 0.659 0.566 0.644 0.649 0.595 0.667
1994 0.618 0.583 0.621 0.567 0.653 0.577 0.502 0.520 0.593 0.470 0.568
1995 0.616 0.567 0.610 0.589 0.605 0.567 0.466 0.498 0.584 0.490 0.557
1996 0.612 0.529 0.532 0.506 0.558 0.550 0.427 0.385 0.557 0.444 0.505
1997 0.584 0.535 0.513 0.464 0.579 0.551 0.425 0.425 0.538 0.411 0.499
1998 0.648 0.511 0.512 0.436 0.526 0.540 0.406 0.364 0.524 0.363 0.475
1999 0.784 0.535 0.456 0.496 0.499 0.521 0.365 0.445 0.548 0.387 0.493
2000 0.601 0.312 0.409 0.373 0.467 0.431 0.299 0.362 0.480 0.263 0.389
2001 0.732 0.388 0.476 0.427 0.566 0.485 0.392 0.367 0.563 0.317 0.458
Annual change rate
0.984 0.951 0.962 0.956 0.970 0.963 0.952 0.949 0.970 0.941 0.960
Table A1.  DEA Efficiencies in Cross-Section DEA by Year
Year Firm
Takeda Sankyo Yama- Daiichi Eisai Shio- Fuji- Chugai Tanabe Yoshi-
nouchi nogi sawa tomi
1982 0.80 1 0.89 0.67 0.74 0.87 0.84 0.81 0.86 0.67
1983 0.84 1 0.89 0.78 0.74 0.88 0.79 1 0.93 0.57
1984 0.83 1 1 0.91 0.69 0.97 1 0.91 0.93 0.84
1985 0.90 1 1 1 0.62 0.80 0.72 0.83 0.86 0.65
1986 0.81 1 0.94 1 0.67 0.82 1 0.83 1 0.65
1987 0.85 1 1 1 0.63 0.78 0.78 0.69 1 0.98
1988 0.80 1 1 0.91 0.60 0.76 0.86 0.68 1 1
1989 0.84 1 1 1 0.72 0.83 0.94 0.60 0.88 1
1990 0.74 1 1 0.90 0.64 0.72 0.84 0.55 0.84 1
1991 0.72 1 0.97 0.80 0.61 0.65 0.84 0.63 0.78 1
1992 0.77 1 0.92 0.88 0.67 0.72 1 0.69 0.96 1
1993 0.82 1 0.86 0.83 0.68 0.78 0.84 0.72 0.94 1
1994 0.83 1 0.98 0.94 0.78 0.93 0.96 0.84 1 1
1995 1 1 1 0.92 0.83 0.94 1 0.81 0.94 0.99
1996 1 1 1 0.94 0.88 0.94 1 0.91 0.95 0.89
1997 1 1 1.00 0.89 0.68 0.85 0.89 0.60 0.99 1
1998 1 1 0.69 0.88 0.58 0.84 0.81 0.74 0.90 1
1999 1 0.93 1 0.98 0.75 1 0.86 0.61 1 0.93
2000 1 0.81 0.74 0.83 0.65 0.79 0.63 0.51 1 0.95
2001 1 0.65 0.67 0.79 0.60 0.83 0.50 0.51 1 0.67
Table A2.  DEA Efficiencies in Time Series DEA by Firm
Year Firm
Takeda Sankyo Yama- Daiichi Eisai Shio- Fuji- Chugai Tanabe Yoshi-
nouchi nogi sawa tomi
1982 1 1 1 1 1 1 1 0.97 1.00 1
1983 1 0.89 0.98 0.92 0.94 0.88 0.91 1 1 0.81
1984 0.90 0.84 0.94 0.89 0.88 1 1 1 0.90 0.73
1985 0.86 0.82 0.91 1 0.83 0.79 0.77 0.84 0.87 0.65
1986 0.84 0.79 0.85 1 0.87 0.79 0.95 0.86 0.97 0.62
1987 0.94 0.74 0.99 1 0.82 0.76 0.74 0.74 1 0.61
1988 0.90 0.77 1 1 0.84 0.76 0.85 0.66 1 0.65
1989 0.77 0.72 0.86 0.92 0.80 0.74 0.76 0.64 0.73 0.93
1990 0.69 0.77 0.78 0.80 0.80 0.65 0.76 0.60 0.73 1
1991 0.64 0.84 0.77 0.75 0.79 0.59 0.66 0.66 0.71 0.82
1992 0.66 0.89 0.80 0.78 0.79 0.61 0.58 0.71 0.71 0.65
1993 0.78 0.96 0.78 0.76 0.80 0.63 0.66 0.71 0.71 0.92
1994 0.63 0.83 0.77 0.73 0.79 0.66 0.62 0.72 0.70 0.86
1995 0.74 0.74 0.79 0.72 0.79 0.67 0.72 0.66 0.64 0.89
1996 0.74 0.92 0.81 0.75 0.88 0.67 0.55 0.60 0.66 0.97
1997 0.73 1.00 0.80 0.71 0.77 0.62 0.51 0.51 0.68 1
1998 0.82 1 0.52 0.68 0.60 0.61 0.48 0.48 0.64 1
1999 0.96 0.86 0.53 0.70 0.58 0.68 0.40 0.46 0.67 0.84
2000 0.94 0.50 0.55 0.62 0.82 0.56 0.31 0.44 0.82 0.78
2001 1 0.46 0.48 0.56 0.81 0.53 0.31 0.40 0.81 0.57
Table A3.  DEA Efficiencies in Panel DEA
Year Firm
Takeda Sankyo Yama- Daiichi Eisai Shio- Fuji- Chugai Tanabe Yoshi-
nouchi nogi sawa tomi
1982 0.76 1 0.82 0.67 0.64 0.83 0.81 0.73 0.78 0.65
1983 0.71 0.89 0.74 0.62 0.58 0.73 0.71 0.78 0.72 0.45
1984 0.65 0.84 0.74 0.60 0.49 0.74 0.63 0.69 0.70 0.46
1985 0.65 0.82 0.68 0.70 0.46 0.64 0.49 0.59 0.65 0.39
1986 0.64 0.79 0.71 0.87 0.52 0.64 0.54 0.60 0.81 0.34
1987 0.73 0.74 0.95 0.94 0.51 0.63 0.58 0.54 0.85 0.37
1988 0.69 0.77 1 0.89 0.53 0.63 0.67 0.44 0.84 0.41
1989 0.59 0.72 0.81 0.81 0.50 0.59 0.51 0.43 0.59 0.67
1990 0.53 0.76 0.73 0.67 0.47 0.52 0.46 0.40 0.58 0.73
1991 0.47 0.81 0.70 0.62 0.47 0.47 0.44 0.44 0.58 0.56
1992 0.51 0.83 0.72 0.62 0.48 0.49 0.45 0.47 0.58 0.36
1993 0.52 0.87 0.68 0.61 0.48 0.51 0.45 0.47 0.56 0.61
1994 0.49 0.76 0.69 0.62 0.49 0.53 0.46 0.48 0.57 0.51
1995 0.57 0.67 0.70 0.61 0.50 0.53 0.42 0.44 0.53 0.53
1996 0.60 0.83 0.73 0.67 0.54 0.54 0.43 0.40 0.55 0.58
1997 0.55 0.92 0.72 0.60 0.47 0.50 0.40 0.34 0.55 0.62
1998 0.70 0.95 0.52 0.58 0.38 0.49 0.38 0.33 0.53 0.59
1999 0.86 0.80 0.51 0.64 0.36 0.49 0.27 0.33 0.54 0.50
2000 0.93 0.45 0.55 0.58 0.45 0.45 0.24 0.33 0.65 0.45
2001 0.99 0.41 0.48 0.52 0.44 0.43 0.24 0.27 0.62 0.33
